Skip to main content

Advertisement

Table 1 Baseline characteristics (safety set)

From: Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study

CategoryN = 495
Age (years); mean ± SD [range]67.7 ± 8.98 [43–87]
Age categories; n (%)
 ≥30 to < 65164 (33.1)
 ≥65 to < 85325 (65.7)
 ≥856 (1.2)
Sex (M/F); n (%)a315 (63.6)/179 (36.2)
Race: n (%)
 White495 (100.0)
Duration of Parkinson’s disease (months);
 Mean ± SD102.1 ± 59.60
 Median [range]89 [5–420]
Duration of motor fluctuations (months);
 Mean ± SD30.1 ± 37.97
 Median [range]15 [0–324]
Symptoms (WOQ-9 assessment); n (%)b
 Tremor299 (62.7)
 Any slowness of movement459 (96.2)
 Mood changes248 (52.0)
 Any stiffness393 (82.4)
 Pain/aching286 (60.0)
 Reduced dexterity433 (90.8)
 Cloudy mind/slowness of thinking223 (46.8)
 Anxiety/panic attacks119 (24.9)
 Muscle cramping288 (60.4)
Total levodopa daily dose (mg); mean ± SD580.1 ± 289.1
Median [range]525.0 [100–3750]
Adjunct therapies; n (%)c
 Rasagiline136 (27.5)
 Pramipexole123 (24.8)
 Ropinirole111 (22.4)
 Amantadine105 (21.2)
 Rotigotine68 (13.7)
 Safinamide67 (13.5)
 Piribedil44 (8.9)
  1. an = 1 missing, bassessed in the full analysis set, cpatients could take ≥ 1 adjunct therapy